Skip to main
IMRX

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immuneering Corp demonstrates a positive outlook primarily due to its innovative approach utilizing its proprietary Disease Cancelling Technology platform, which enhances drug discovery processes for oncologic and neurologic diseases, potentially leading to groundbreaking treatments. Recent clinical data suggest significant improvements in patient outcomes for those receiving atebimetinib in combination with established regimens, showcasing a favorable tolerability profile, which bodes well for progression into later-stage trials and broader applications. Furthermore, the company benefits from a substantial total addressable market of over $12 billion across the cancers being targeted, alongside a strategic extension of its developmental runway into 2029, which allows for thorough execution of its clinical trials.

Bears say

The analysis of Immuneering Corp indicates significant regulatory risks that could lead to downward revisions in financial projections if the company's products fail to receive necessary approvals or do not demonstrate improved efficacy compared to existing treatments. Additionally, there is a concern regarding the potential need for the company to raise capital through equity financings before achieving profitability, which could result in share dilution for existing shareholders. Lastly, the possibility of receiving regulatory approval for narrower indications or facing costly post-approval requirements further complicates the outlook, exposing the company to additional financial uncertainties.

Immuneering Corp (IMRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Buy based on their latest research and market trends.

According to 6 analysts, Immuneering Corp (IMRX) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.